Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lymphoma × sapanisertib × Clear all

Phase

Status

Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Nonhematological Neoplasms 1

Interventions

Rituximab 58 Cyclophosphamide 47 fludarabine phosphate 23 fludarabine 20 Filgrastim 20 Methotrexate 18 Melphalan 18 Radiotherapy 17 Etoposide 17 Vincristine 16 Doxorubicin 15 Cytarabine 14 Whole-Body Irradiation 13 Tacrolimus 13 Prednisone 13 Peripheral Blood Stem Cell Transplantation 13 Mycophenolic Acid 13 Cyclosporine 13 Antilymphocyte Serum 13 Gemcitabine 12 Lenalidomide 11 Busulfan 10 Bortezomib 9 Granulocyte Colony-Stimulating Factor 8 Dexamethasone 8 Cord Blood Stem Cell Transplantation 8 sargramostim 7 Vorinostat 7 Methylprednisolone 7 Carmustine 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡